# Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

> **NCT04102982** · PHASE2 · UNKNOWN · sponsor: **Shandong Provincial Hospital** · enrollment: 200 (estimated)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **DRUG:** Camrelizumab
- **OTHER:** Camrelizumab plus microwave ablation

## Key facts

- **NCT ID:** NCT04102982
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-02-28
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102982, "Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04102982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*